Skip to main content

PERSPECTIVE article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1487709
This article is part of the Research Topic Use of Big Data and Artificial Intelligence in Multiple Sclerosis View all 6 articles

Artificial Intelligence science of patient input: a perspective from people with multiple sclerosis

Provisionally accepted
Anne Helme Anne Helme 1Dipak Kalra Dipak Kalra 2Giampaolo Brichetto Giampaolo Brichetto 3Guy Peryer Guy Peryer 4Patrick Vermersch Patrick Vermersch 5Helga Weiland Helga Weiland 6Angela M. White Angela M. White 7Paola Francesca Maria Zaratin Paola Francesca Maria Zaratin 3*
  • 1 Multiple Sclerosis International Federation (MSIF), London, United Kingdom
  • 2 The European Institute for Innovation through Health Data, Gent, Belgium
  • 3 Italian MS Society, Rome, Italy
  • 4 University of East Anglia, Norwich, England, United Kingdom
  • 5 Université de Lille, Lille, Nord-Pas-de-Calais, France
  • 6 Multiple Sclerosis South Africa, Krugersdorp, South Africa
  • 7 National Multiple Sclerosis Society, New York, New York, United States

The final, formatted version of the article will be published soon.

    Artificial intelligence (AI) can play a vital role in achieving a shift towards predictive, preventive, and personalized medicine, provided we are guided by the science with and of patient input. Patient reported outcome measures (PROMs) represent a unique opportunity to capture experiential knowledge from people living with health conditions and make it scientifically relevant for all other stakeholders. Despite this, there is limited uptake of the use of standardized outcomes including PROMs within the research and healthcare system. This perspective article discusses the challenges of using PROMs at scale, with a focus on multiple sclerosis. AI approaches can enable learning health systems that improve the quality of care by examining the care health systems presently give, as well as accelerating research and innovation. However, we argue that it is crucial that advances in AI whether relating to research, clinical practice or health systems policy are not developed in isolation and implemented 'to' people, but in collaboration 'with' them. This implementation of science with patient input, which is at the heart of the Global PROs for Multiple Sclerosis (PROMS) Initiative, will ensure that we maximize the potential benefits of AI for people with MS, whilst avoiding unintended consequences.

    Keywords: artificial intelligence, Patient Reported Outcomes, Health Outcomes, Multiple Sclerosis, Ethics

    Received: 28 Aug 2024; Accepted: 28 Jan 2025.

    Copyright: © 2025 Helme, Kalra, Brichetto, Peryer, Vermersch, Weiland, White and Zaratin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Paola Francesca Maria Zaratin, Italian MS Society, Rome, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.